Formulary Group work programme

Forthcoming submissions 2014

This list is indicative and may be subject to change.

Adalimumab - SMC 881/13 -  in progress. (Indication: in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs)).

Alemtuzumab - SMC 959/14 - in progress. (Indication: For adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features).

Aripiprazole - SMC 891/13- in progress. (This SMC advice relates to an extension of the marketing authorisation for treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older).

Aripiprazole - SMC 962/14 - in progress. (Indication: maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole).

Atomoxetine - SMC 909/13 - in progress. (Indication: treatment of attention-deficit/hyperactivity disorder (ADHD) in adults as part of a comprehensive treatment programme).

Beclometasone dipropionate/formoterol fumarate dehydrate (Fostair®) - SMC 976/14 - in progress. (Indication: symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators).

Budesonide - SMC 970/14 - in progress. (Indication: induction of remission in patients with mild to moderate active Crohns disease affecting the ileum and/or ascending colon).

Canagliflozin - SMC 963/14 - Formulary Group advice will be published by 29th July 2014. (Indication: in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as add-on therapy with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control).

Certolizumab  pegol - SMC 973/14 - in progress (Indication: in combination with methotrexate, for the treatment of active psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug (DMARD) therapy has been inadequate).

Defibrotide- SMC 967/14 - Formulary Group advice will be published by 29th July 2014. (Indication: treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy).

Eltrombopag - SMC 919/13 - in progress. (Indication: in adult patients with chronic hepatitis C virus infection, for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy).

Fesoterodine - FG1354/14 - in progress. (Indication: Bladder overactivity).

Jaydess® - Formulary Group advice will be published by 29th July 2014. (Indication: IUS - contraception).

Nalmefene - SMC 917/13 - in progress. (Indication: for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms, and who do not require immediate detoxification).

Ondanestron - SMC 912/13 - in progress. (Indication: in adults: Prophylaxis and treatment of acute and delayed nausea and vomiting induced by chemotherapy, and radiotherapy. Prophylaxis and treatment of post-operative nausea and vomiting.
In paediatric populations:Management of chemotherapy-induced nausea and vomiting in children aged ≥6 months and prophylaxis and treatment of post-operative nausea and vomiting (PONV) in children aged ≥4 years).

Rituximab subcutaneous injection - SMC 975/14 -  in progress. (Indication: for non-Hodgkin's lymphoma (NHL) in adults).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.


« Previous: Formulary Group | Top | Next: Formulary Group decisions index »